Lantern Pharma (LTRN) Expected to Announce Quarterly Earnings on Thursday

Lantern Pharma (NASDAQ:LTRN) is expected to be announcing its Q2 2025 earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter.

Lantern Pharma (NASDAQ:LTRN) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.07. During the same period in the prior year, the business earned ($0.51) EPS. On average, analysts expect Lantern Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Lantern Pharma Stock Down 1.2%

Shares of NASDAQ LTRN opened at $5.14 on Thursday. The firm’s fifty day moving average is $3.62 and its 200 day moving average is $3.78. Lantern Pharma has a 52 week low of $2.55 and a 52 week high of $6.12. The company has a market cap of $55.41 million, a price-to-earnings ratio of -2.79 and a beta of 1.60.

Insider Transactions at Lantern Pharma

In other news, major shareholder Leslie W. Kreis sold 40,000 shares of the firm’s stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $3.09, for a total value of $123,600.00. Following the completion of the sale, the insider directly owned 49,957 shares of the company’s stock, valued at approximately $154,367.13. This trade represents a 44.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Aaron G.L. Fletcher sold 40,000 shares of the business’s stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $3.09, for a total transaction of $123,600.00. Following the transaction, the insider owned 49,957 shares in the company, valued at $154,367.13. This represents a 44.47% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 315,700 shares of company stock valued at $1,000,580. 7.31% of the stock is currently owned by company insiders.

About Lantern Pharma

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.